Need professional-grade analysis? Visit stockanalysis.com
$18.43B
N/A
208
N/A
Ascletis Pharma Inc (1672) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD18.19, down 1.57% from the previous close.
Over the past year, 1672 has traded between a low of HKD5.48 and a high of HKD18.48. The stock has gained 182.9% over this period. It is currently 231.9% above its 52-week low.
Ascletis Pharma Inc has a market capitalization of $18.43B.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
Side-by-side comparison against top Healthcare peers.